Safety profile of fluvastatin

British Journal of Clinical Practice

Volumn , Issue SUPPL. 77a, 1996, Pages 20-23

  Peters, T K ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADULT; AGED; CATARACT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CATARACT; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0029715983     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Bluni CB. Comparison of properties of (bur inhibitors of 3-hydroxy3-methylglutaryl-coenzyme A reductase. Am .1 Cunlitil 1944: 7.1: 3D-11D.
2. Sandoz. Data on file.
3. Peter-, TK. Mehra M. Muratti EN. Efficacy and safety of fluvaslulin in hypertensive patients: an analysis of a clinical trial database. Am J Hypertens 199.1; 6: 340S-345S.
4. Peters TK, Jewitt-Harris J. Mehra M. Muratti EN. Safety andtolerability of fluvaslatin with concomitant use of antihypenensive agents: an analysis of a clinical trial database. Am J Hypertens 1993; 6: 346S-352S.